I’ve long held the notion, and am hardly original in it, that the accumulation of data to understand launch efficiency must at some point entail real changes to the shape of those launches. The halcyon blockbuster days of laying out a billion or more and splashing ads everywhere would ultimately meet up with the performance analytics, grown ever keener in both commercial and ad-land, and the latter would come down on the former like a wolf in the fold. It’s just simple maths you see, it’s the question that keeps an analytical mind entertained — what is the inflection point on the yield of promotion and sales effort at which point your next dollar in would account for less than a dollar back (well, less than whatever your marketing ROI target is, anyway). The recent (vintage August) launch of two brands serves as just such a “natural experiment” in how those changes in tactics are unfolding.
Today’s most anticipated therapies — especially across targeted oncology and rare autoimmune diseases — operate under fundamentally different rules. Modern launches do not build an audience from scratch; they mobilize and convert pre-identified clinical cohorts.
To evaluate this paradigm shift, this analysis examines the real-world commercial trajectories of two major specialty therapies approved in August 2026: Rasonque (indicated for metastatic pancreatic adenocarcinoma) and Lisraya (indicated for adult dermatomyositis). Both target rare disease, meaning under 200k patients per the orphan drug act’s guidance, but in this case closer to 5,000 to 50,000. Longitudinal claims demonstrate where conventional commercial assumptions hold, where they fail, and how forward-looking launch teams must adapt their commercial models.
Key historical and structural differences
1. The audience is known before day one
In the blockbuster model, commercial spend was front-loaded to manufacture diagnostic awareness. In precision commercialization, the patient population is already active within the healthcare system, requiring conversion and navigation rather than broad demand creation.
Oncology trajectory (Rasonque). Over 2,000 early-adopting patients accessed therapy through expanded access and compassionate use programs prior to formal regulatory approval. From day one, execution centered on converting active clinical trial and compassionate-use patients onto commercial drug and securing reimbursement, rather than discovering new candidates.
Rare disease trajectory (Lisraya). The eligible adult patient population is largely diagnosed and currently managed on baseline therapies, including high-dose systemic corticosteroids, immunosuppressants, or intravenous immunoglobulin (IVIG). Commercial success hinges on pinpointing the specific specialists managing therapy-refractory patients rather than general disease awareness campaigns.
Strategic implication: precision launch budgets must prioritize data-driven patient and prescriber identification over broad top-of-funnel reach.
2. Access, not awareness, sets launch velocity
In specialty and precision launches, the primary attrition point does not occur between promotion and the physician’s intent to treat. Instead, it occurs between the written prescription and the pharmacy counter.
Fulfillment velocity. For patients with verified insurance coverage, Rasonque demonstrates swift conversion, with a median of 0 to 2 days to first fill. However, approximately 1 in 4 insured attempters remains stalled beyond 30 days due to plan documentation cycles and prior authorization reviews.
Payer friction. In Lisraya’s rare immunology landscape, government-insured patients (Medicare and Medicaid) absorb a median of 5 to 8 rejected claims or re-authorizations before securing an approved first fill.
Strategic implication: cross-functional commercial dashboards must track access velocity metrics — including time-to-first-fill, first-attempt paid rates, and regional denial trends — alongside traditional prescription volumes.
3. Commercial budgets have migrated to the decision point
With specialty drug commercial budgets experiencing downward pressure of 10% to 25%, brand leaders are reallocating capital away from linear broadcast channels directly into clinical decision-support environments.
Channel reallocation. Marketing spend has shifted course, with approximately 70% allocated toward HCP engagement and point-of-care platforms, compared to 30% for targeted patient engagement.
High-impact surfaces. Investments are concentrated in electronic health record (EHR) clinical decision prompts, integrated workflow alerts, and peer-to-peer specialty digital networks. In my day there was talk of “high impact ad units” as different shapes of ad that could be placed within the same digital framework; what’s happening now instead is we’re measuring the value of a message differently depending on where it appears, how distal it is to the clinical decisioning.
Demonstrated return. ROI measurement becomes even more essential for physician engagement, where the populations that need to be engaged are so small and the cost to reach them becomes correspondingly higher.
Strategic implication: meeting the physician at the exact moment of treatment evaluation yields significantly higher conversion than broad awareness media.
4. “Precise” does not mean “concentrated”
The most persistent misconception in specialty pharmaceutical launch planning is assuming that a small patient population is concentrated entirely within 100 to 200 academic Centers of Excellence. Real-world claims tell a markedly different story.
Community oncology penetration. Rasonque was adopted by over 1,800 oncologists across all 50 states within its opening weeks. Approximately 60% of all starts occurred in community oncology practices, with the top ten largest institutions accounting for only a single-digit percentage of total treatment volume.
The long tail in rare disease. Lisraya established an active prescriber footprint spanning dozens of states immediately following approval. Reaching half of all potential dermatomyositis starts requires engaging an active specialty cohort of over 650 physicians.
Cross-specialty prescribing. While rheumatology is considered the primary specialty for systemic dermatomyositis management, over one-third (36%) of initial commercial writers were dermatologists treating severe cutaneous manifestations.
Strategic implication: build territory alignments, field coverage, and digital campaigns around active patient volume in claims rather than static Key Opinion Leader (KOL) rosters. Real-world specialty uptake exhibits an extensive, national long tail.
A modest modern launch execution checklist
- Fund identification over awareness. Direct launch capital toward locating active, diagnosed patients and their treating clinicians through longitudinal claims before committing to mass media campaigns.
- Align commercial execution with regional access hurdles. Adapt field sales messaging and patient navigation resources to specific geographies and plans with elevated prior authorization friction.
- Engage the full multi-disciplinary team. Identify and engage secondary specialties early (e.g. dermatologists in dermatomyositis) who identify eligible clinical candidates prior to primary specialist referral.
- Measure net paid starts and persistence. Measure marketing and commercial success by verified paid claims, therapy adherence, and real-world persistence rather than vanity impressions or broad reach.
Methodology and data notice
Findings in this report are derived from PurpleLab’s longitudinally active national healthcare claims database, representing a highly correlated, statistically robust cross-section of the U.S. clinical market. Observed patient and prescriber volumes serve as stable real-world indices of clinical adoption and are designed to illustrate structural market dynamics without disclosing raw panel denominators.
Visit purplelab.com for more, or contact tsweetser@purplelab.com.
Originally published on LinkedIn.